This StubHub stock analysis walks through why STUB’s setup eight months after its NYSE debut is worth a fresh look: the share price has crashed, two of the three obvious catalysts have already played out, and the Q1 2026 earnings beat in May has changed the question from “will anything good happen?” to “did the worst already happen?”

STUB

--

Published$7.71·May 18·

1D5D1W1M3M6M1Y

Data: Yahoo Finance

Orbit – our AI-augmented research engine – captured STUB at $7.71 on May 18, 2026, which puts the stock down roughly 67% from its $23.50 IPO price set in September 2025. We don’t think the price itself is the interesting part of the story; the catalyst calendar is. We’ll map out three concrete event windows that decide whether this is a value setup, a value trap, or something in between – and two ways the thesis breaks.

Why this StubHub stock analysis matters now

The short version: STUB Holdings went public on the NYSE on September 17, 2025 at $23.50 per share – the exact mid-point of its $22-$25 range – and raised $800 million at a roughly $8.6 billion market valuation. The stock popped 7.9% on debut day, then began a long grind lower that bottomed near $5.74 sometime around the March 6, 2026 lock-up expiry. Today it trades around $7.71-$8.82, recovering on a stronger-than-expected Q1 2026 earnings print delivered May 13.

If you had only read the headlines you’d think this was a busted IPO. If you had only read the Q1 release you’d think this was a comeback story. Both are partial. The fuller picture is that the catalyst calendar STUB watchers were waiting on has substantially compressed in the last three months – the DOJ antitrust case resolved in a settlement, the lock-up cleared, and the first post-IPO earnings cycle proved unit economics. What’s left isn’t “will anything happen?”; it’s whether the things that already happened were enough to mark structural support.

What StubHub actually does

StubHub is a two-sided secondary ticket marketplace. Sellers – season-ticket holders, brokers, the occasional fan who can’t make it – list seats; buyers find them; StubHub takes a cut on both sides. The implied net take rate in Q1 2026 was about 20.3% ($446 million of revenue against $2.2 billion of gross merchandise sales), per the company’s earnings release. That’s the lever the whole business runs on.

The company runs two brands on one underlying platform: the StubHub brand serves North American customers, and Viagogo – the brand that bought it from eBay for $4.05 billion in November 2019 – handles the international footprint. Viagogo CEO Eric Baker actually co-founded StubHub in 2000 before leaving the company; eBay bought StubHub for $310 million in 2007 and sold it back to Baker’s Viagogo twelve years later. The IPO is Baker re-introducing the combined entity to public markets after a long detour.

Verticals split across concerts, sports, and theater. Concerts are the largest category by GMS; sports is the second; theater and comedy round out the mix. (We’re working off general industry framing here – the exact disclosed percentages live inside StubHub’s S-1 and 10-Q filings on EDGAR, and shift quarter to quarter with the touring calendar.) Why this matters: take-rate-on-transaction is a margin model, not a subscription model. It’s sensitive to event volume swings, average ticket prices, and – critically – to competitive fee pressure.

The post-IPO trajectory was not “drift”

The pattern shown in the chart above isn’t gentle post-IPO drift – it’s a full-on first-year crash. From the $23.50 IPO mark, STUB ground steadily lower through late 2025 and into Q1 2026, hitting a 52-week low near $5.74. A Q4 2025 earnings miss in early March – reported alongside the formal lock-up expiry on March 6, 2026 – was the bottom. The mechanical reason isn’t mysterious: when a chunk of pre-IPO insiders all get permission to sell on the same date, you get a structural supply overhang, and Q4 numbers gave the market a reason to absorb that overhang at lower prices.

For comparison, ticketing peer Vivid Seats (NASDAQ: SEAT) went public via SPAC merger with Horizon Acquisition in October 2021 and saw a similar multi-quarter post-listing slide. The point isn’t that STUB will mirror SEAT exactly; it’s that “post-IPO crash followed by a fundamentals-driven recovery attempt” is the normal pattern for a marketplace business that prices a premium SPAC-era multiple onto pre-revenue-momentum financials.

What changed in May was the Q1 2026 print. Revenue grew 12% year-over-year to $446 million; GMS grew 7% to $2.2 billion; adjusted EBITDA was $72.1 million for a 16% margin, expanding more than 400 basis points; and the company swung from a $22.2 million net loss in the prior-year quarter to $48 million of net income. Operating cash flow was $298.4 million, free cash flow $290.6 million. Management reaffirmed full-year 2026 guidance of $9.9-$10.1 billion GMS and $400-$420 million adjusted EBITDA. The stock popped roughly 19.8% on the print, which is what got us writing this post.

Three catalysts that decide the trajectory from here

Catalyst 1 – The Live Nation state-level remedy phase

This is the catalyst people keep talking about, but the framing has moved. The DOJ filed antitrust suit against Live Nation/Ticketmaster on May 23, 2024, alleging monopolization of live concert markets. Then on March 9, 2026 the DOJ announced a tentative settlement: Live Nation would pay up to $280 million in fines, divest 13 amphitheater venues, cap Ticketmaster fees at 15% of face value, and open its platform to competitors. Ticketmaster itself was not required to be sold. A coalition of state attorneys general – more than two-thirds of US states plus Washington D.C. by the time the trial resumed – rejected the settlement and continued the trial. On April 15, 2026 a federal jury found Live Nation liable on the states’ antitrust claims. The remedy phase is now under Judge Arun Subramanian.

For STUB, the pending element is the remedy ruling, not the verdict. The two outcomes that matter are: (1) whether the judge orders structural relief beyond what the DOJ settlement already extracted, and (2) whether the 15% fee cap propagates beyond Ticketmaster to the rest of the ticketing industry through follow-on litigation. The first is direct TAM expansion for the secondary market; the second is a downside vector that could compress STUB’s own roughly 20% take rate. Both come into focus over the next eight to twelve months, with the remedies hearing itself the key inflection.

Catalyst 2 – Take-rate stability versus competitive fee pressure

STUB’s roughly 20% net take rate is the single most important number in the business model. SeatGeek (private) and Vivid Seats (NASDAQ: SEAT) have been undercutting on buyer fees for several quarters; the DOJ’s 15% cap on Live Nation’s primary-market fees is now the regulatory precedent everyone in the room can point at. If that precedent migrates – through state-level remedies, consent decrees, or simple competitive pressure – STUB’s net take rate has nowhere to go but down.

The thing to watch is segment-level take rate in upcoming 10-Q filings. Management hasn’t yet had to disclose this granularly, but as the public-company filing cadence matures and analysts get more pointed on competitive-dynamics questions, the bear case becomes “show us the take rate is stable, quarter over quarter, in concerts and sports separately.” If take rate compresses 200 basis points – from 20.3% toward 18% – the unit economics flip from being leverageable on volume growth to being roughly break-even on incremental revenue. That’s the threshold that turns the Q1 beat from a regime shift into a one-quarter blip.

Catalyst 3 – Q2 2026 earnings and the post-lockup clearance test

The original Catalyst 3 most analysts wrote about – “what does the lock-up expiry do?” – has already happened. Lock-up agreements ended at the close of business March 6, 2026, with certain preferred share conversions following the IPO-plus-180-days clock around March 17. STUB cratered through both dates. The supply overhang did exactly what supply overhangs do.

The actually pending question is Q2 2026 earnings, expected in August 2026 (date to be confirmed by the company). The Q1 beat could be one quarter, helped by favorable touring calendar comps and a quirk of cost timing – or it could be the first quarter of a sustained margin-expansion regime that the new public-company discipline forces. Q2 prints either confirm the inflection or invalidate it. Watch the same three lines: revenue growth, take rate (implied from revenue/GMS), and EBITDA margin trajectory. A second quarter of 12%-plus revenue growth, stable take rate, and EBITDA margin holding above 15% would be enough for institutional money to start treating Q1 as the start of a regime, not an outlier.

Two risks that invalidate the setup

Risk 1 – Discretionary spending collapses, with a delay

The cliche about live entertainment is “concerts are the first thing people cut in a recession.” The cliche is wrong. Pollstar’s 2008 business analysis shows North American concert ticket sales hit a record $4.2 billion in 2008 (up roughly 7% year-over-year) right through the financial crisis; 2009 set fresh records for Top 100 tour grosses; the actual decline was 2010, when total revenue fell roughly 8% to $4.25 billion – the first concert-industry revenue decline since 1995.

That delay is a feature of how live events get bought. Tours are booked 12-18 months in advance; tickets are committed months ahead of the event itself; the cancellation cost is high enough that consumers cut almost everything else first. So the real recession risk for STUB isn’t an immediate macro shock – it’s the cycle where 2026-2027 macro stress shows up as 2028 concert-revenue weakness, by which time multiple quarters of guidance will need to be reset downward. The threshold to watch is any sustained -5% year-over-year concert revenue print starting 12-18 months after a major macro shock, in either the Pollstar data or Live Nation’s same-store metrics.

Risk 2 – The state remedy phase produces nothing structural

The bull case for STUB on antitrust assumes Judge Subramanian orders structural relief that goes beyond the DOJ’s settlement – tighter limits on venue-exclusive contracts, broader fee caps that apply industry-wide, or in the maximal case, divestiture of Ticketmaster from Live Nation. The bear case is that the remedy ends up being mostly monetary, that appeals stretch the timeline three to five years, and that the 15% fee cap stays narrowly scoped to Live Nation’s primary-market business.

If that’s what happens, two things follow. The TAM-expansion narrative dies – the secondary market keeps doing what it was already doing, no structural lift. And the 15% fee cap becomes a one-way street: it pressures STUB’s own take rate without giving STUB any volume offset. That combination is what would turn a 20% net take rate into an 18% one over 18-24 months, and shift STUB from leverageable to roughly break-even on incremental revenue. The catalyst-calendar setup becomes a value trap.

How a systematic investor would monitor this

The framework here isn’t “is STUB a buy?” – we don’t think that’s the question an honest analyst can answer in a public post. The framework is: which dated events over the next twelve months produce the most information about whether the thesis holds, and what specifically should you look for in each one?

Three dated windows. Q2 2026 earnings (~August 2026) – is the Q1 beat one quarter or the first quarter of a regime? Judge Subramanian’s remedy hearing (the judge has indicated as early as February 2027, with the ruling and any appeals likely stretching further into 2027-2028) – does the structural relief expand or does the case wrap up cleanly with monetary remedies only? Q3-Q4 2026 10-Q filings – do the take-rate disclosures hold near 20% or does the implied number start drifting lower as competitive pressure compounds?

This is the same playbook Luna3 used to walk through our four-catalyst single-ticker setup on GLSI and our earlier structural thesis on bitcoin miners converting to AI infrastructure – identify the dated events, set falsifiable thresholds for each one, and accept that the answer might come back as “thesis broken.” Position sizing matters more than entry price in catalyst-driven setups, because the variance is in whether the catalyst happens at all, not in whether you got the entry exactly right.

And if single-ticker catalyst trades aren’t your thing – if you’d rather not have idiosyncratic exposure to one ticketing marketplace surviving a multi-year remedy phase – the broader US-equity exposure inside something like a total-market ETF such as VOO or VTI gives you the macro return without the catalyst risk. That’s a fine answer too. The framework doesn’t require you to buy STUB; it requires you to know what would have to be true for you to buy STUB, and how you’d know if you were wrong.

The bottom line

STUB at $7.71 is not the value setup the headline 67% decline from IPO suggests. It’s a marketplace business that priced its IPO at the mid-point of a $22-$25 range, lost two-thirds of its market cap through ordinary post-IPO mechanics (Q4 miss, lock-up overhang), and then printed a Q1 result that confirmed unit economics work. The catalyst calendar has narrowed – the DOJ case is done, the lock-up is done – but the remaining catalysts are more dated and arguably more institutional-investor-relevant. The next twelve months produce concrete answers on the take-rate compression risk, the state-level remedy structure, and whether Q1’s profitability is one quarter or a regime.

What would need to be true for the catalyst-calendar setup to play out: take rate holds near 20% through Q2 and Q3 2026, the state remedy phase produces structural relief beyond the DOJ settlement, and concert-industry revenue holds positive year-over-year through 2027. What would invalidate it: take rate compresses below 19% in any of the next two prints, the state remedy phase ends in monetary-only damages, or 2027 concert revenue prints negative. The next diagnostic data point is Q2 2026 earnings, roughly twelve weeks out.